Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects with mild to moderate AD 18 to 65 years of age, inclusive.~2. AD diagnosed by physician / medical specialist and that has been (intermittently) present for at least 1 year~3. Able to participate and willing to give written informed consent and to comply with the study restrictions.~Exclusion Criteria:~1. Have any current and / or recurrent clinically significant skin condition in the treatment area other than AD.~2. Any confirmed, active significant allergic reactions (urticaria or anaphylaxis) including allergic reactions against any drug, multiple drug allergies or (ingredients of) emollients.~3. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CLS001 topical gel, 2.5% (Type: EXPERIMENTAL): None
- CLS001 topical gel 1% (Type: EXPERIMENTAL): None
- Vehicle gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).